Document:

EX-10.39

 

Exhibit 10.39

Dr Daryl Granner

Vanderbilt University Medical Centre

707 Light Hall

Nashville

Tennessee 37232

USA

1st January 2008

Dear Sirs

Scientific Advisory Board and Consulting
Agreement, dated as of 10th February 2006
between Prosidion Limited and Dr Daryl Granner (the “Agreement”)

This letter will serve as notice of our desire to renew the term of the Agreement for an additional
twelve-month period, from 1st January 2008 through to 31st December 2008.
All other terms and conditions of the Agreement will remain in full force and effect.

Please indicate your agreement to the foregoing by having both copies of this letter signed by an
authorized representative of your company and returning one original, fully signed copy for the
attention of Sian Bishop, General Counsel to the address listed above.

	 	 	 	 	 
	SIGNED for and on behalf of:

PROSIDION LIMITED	 	 
	 
	 	 	 	 
	By:

	 	/s/ Anker Lundemose
 

                (Signature)
	 	 
	 

	 	Dr. A. Lundemose
 

                (Name Printed)
	 	 
	 

	 	1st January 2008
 

	 	 
	 

	 	               (Date)	 	 
	 
	 	 	 	 
	ACCEPTED AND AGREED:

DR DARYL GRANNER	 	 
	 
	 	 	 	 
	By:

	 	/s/ Darryl K. Granner
 

                (Signature)
	 	 
	          

	 	Daryl K. Granner
 

                (Name Printed)
	 	 
	 

	 	1-09-08
 

               (Date)EX-10.55

 

Exhibit 10.55

ADDENDUM TO EMPLOYMENT OFFER

FOR LINDA E. AMPER

CHANGE OF CONTROL AGREEMENT

This Change of Control Agreement, dated December 4, 2007, between OSI Pharmaceuticals, Inc. (“OSI”)
and Linda E. Amper, Ph.D., provides as follows:

In the event OSI is sold or merged with another company resulting in a change of control (a “Change
of Control”), the following shall apply:

	 	1.	 	All of your outstanding unvested options shall vest and be fully exercisable; and
	 
	 	2.	 	If your employment with the controlling company is terminated (including if
you voluntarily terminate your employment for “Good reason”*) at any time
within six (6) months following a Change of Control transaction, unless such termination is
for “cause”, death, disability or you voluntarily leave without
“Good Reason,” you will be entitled to receive the benefits described below:

(i) A lump sum severance payment equal to your annual salary for a period of twelve (12)
months;

(ii) your pro-rated bonus;

(iii) all unpaid, accrued vacation through the date of termination; and

(iv) continued coverage for you and your dependents for twelve (12) months following
termination with health benefits substantially similar to those which you and your
dependents were receiving immediately prior to the sale or

Change of Control.

*    Good Reason for termination of employment includes (i) a decrease in your total compensation
package, (ii) the assignment of duties or responsibilities which are not commensurate with your
position immediately prior to the sale or Change of Control, or (iii) you are required to relocate
to an office or facility more than forty (40) miles from your present location or forty (40) miles
from your home.

	 	 	 	 	 	 	 	 	 
	OSI Pharmaceuticals, Inc.	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	By:

	 	/s/ Colin Goddard
 

Colin Goddard
	 	 	 	/s/ Linda E. Amper
 

Linda E. Amper, Ph.D.
	 	 
	 

	 	Chief Executive OfficerEX-10.56

 

Exhibit 10.56

OSI PHARMACEUTICALS, INC.

CONSULTING AND CONFIDENTIAL DISCLOSURE AGREEMENT

     This Consulting and Confidential Disclosure Agreement (“Agreement”) is effective as of the
23rd day of August, 2007 (“Effective Date”) by and between OSI Pharmaceuticals, Inc., a
Delaware corporation (together with its subsidiaries, “OSI”), having executive offices at 41
Pinelawn Road, Melville, New York 11747, and Walter M. Lovenberg, Ph.D., an individual
(“Consultant”).

1. Nature of Consulting Services. Consultant will provide such corporate governance, research and
development, strategic planning, management and other related services as the Company may request
during the term of this Agreement (the “Services”).

2. Delivery of Consulting Services. Consultant will carry out the Services to the best of
Consultant’s ability in a professional manner consistent with industry standards, in accordance
with the standard of care customarily observed with regard to such services in Consultant’s
profession and using the Consultant’s expertise and creative talents. Consultant will perform
Services in a timely manner and at a location, time and place that Consultant deems appropriate.
Consultant will perform the Services in compliance with all applicable laws, rules and regulations.

3. Compensation and Reimbursement.

     (a) OSI will pay Consultant at a rate of two thousand five hundred dollars ($2,500) for each
day that the Consultant provides Services. The parties anticipate that Consultant will provide
Services for approximately 12 days per year during the term, but the Company shall have sole
discretion as to the amount of Services that it requests from Consultant.

     (b) OSI will reimburse Consultant for reasonable out-of-pocket expenses incurred while
Consultant is traveling at OSI’s request. Consultant must submit copies of appropriate receipts to
OSI for any out-of-pocket expenses greater than twenty-five dollars ($25).

4. Confidentiality.

     (a) “Confidential Information” means confidential or proprietary information of OSI either
disclosed orally, graphically, in writing, or in electronic or other form to or otherwise learned
by Consultant under this Agreement or that should reasonably be known to be confidential or
proprietary to OSI, including but not limited to information relating to OSI’s: research,
development, preclinical and clinical programs, data and results; pharmaceutical or biologic
candidates and products; inventions, works of authorship, trade secrets, processes, conceptions,
formulas, patents, patent applications and licenses; intellectual property rights; business,
product, marketing, sales, scientific and technical strategies, programs and results, including
costs and prices; suppliers, manufacturers, customers, market data, personnel, and consultants; and
other confidential matters related to OSI.

     (b) Subject to Section 4(c), until ten (10) years after the expiration or termination of this
Agreement, Consultant:

          (i) shall not use Confidential Information for its own benefit or the benefit of any third
party except solely for the purpose of performing Services;

          (ii) shall hold Confidential Information in strictest confidence and shall not disclose
Confidential Information to others, except to its employees or agents who require Confidential
Information solely for the purpose of performing Services and who are subject to binding
obligations of confidentiality and restricted use at least as protective as those of this

 

 

Agreement;

          (iii) shall protect the confidentiality of Confidential Information using at least the same
level of efforts and measures used to protect its own confidential information, and at least
commercially reasonable efforts and measures, including without limitation limiting access to
Confidential Information commensurate with performance of the Services and keeping adequate records
of those with access to Confidential Information and of all uses or dispositions of Confidential
Information; and

          (iv) shall notify OSI as promptly as practicable of any unauthorized use or disclosure of
Confidential Information.

     (c) Consultant’s obligations under Section 4(b) shall not apply to any Confidential
Information that:

          (i) Consultant knew prior to learning it under this Agreement, as demonstrated by written
records predating the date it was learned under this Agreement (unless learned from OSI or a third
party under a binder of confidentiality);

          (ii) is now, or becomes in the future, publicly available other than by an act or omission of
Consultant; or

          (iii) a third party discloses to Consultant as a matter of right, without any restriction on
disclosure, and without any breach of any direct or indirect obligation of confidentiality to OSI,
as shown by Consultant’s written records contemporaneous with such third party disclosure.

     (d) Notwithstanding other provisions of this Agreement, Consultant may disclose Confidential
Information to the extent and to the persons or entities required under applicable governmental
law, rule, regulation or order, provided that Consultant (i) first gives prompt notice of such
disclosure requirement to OSI so as to enable OSI to seek any limitations on or exemptions from
such disclosure requirement and (ii) reasonably cooperates at OSI’s request in any such efforts by
OSI.

     (e) Upon the earlier of the completion of the Services or OSI’s request for any reason at any
time, Consultant will (i) immediately cease all use of Confidential Information and notify OSI and
(ii) promptly, at OSI’s instruction, either return to OSI or destroy all Confidential Information,
including any copies, extracts, summaries, or derivative works thereof, and certify in writing to
OSI the completion of such return and/or destruction.

     (f) OSI retains all right, title and interest in and to Confidential Information. This
Agreement gives Consultant no right or license to any Confidential Information or any intellectual
property or other rights owned by or licensed to OSI, by implication or otherwise, except the right
to use Confidential Information solely for performance of Services. OSI may freely transfer,
disclose and/or use Confidential Information for its or others’ purposes.

     (g) Consultant acknowledges that any actual or threatened breach of this Section 4 will cause
OSI immediate and irreparable harm that cannot be adequately compensated by monetary damages, and
Consultant therefore agrees that OSI shall have the right to secure equitable and injunctive relief
under this Agreement in addition to any other remedies that may be legally available.

5. Representation and Warranties. Consultant represents and warrants to OSI that:

     (a) Consultant has the full right, power and authority to enter into this Agreement and
perform its obligations hereunder without the consent of any third party and without breach of any
agreements with or obligations to any third party;

2

 

     (b) Consultant has not entered and will not enter into any agreement with or obligation to a
third party (e.g., a university or corporation) inconsistent, incompatible, or conflicting with its
obligations under this Agreement; and

     (c) Consultant will inform OSI immediately of any contracts or subject matter with which
Consultant or, if Consultant is an individual, members of Consultant’s family are engaged in, that
may in any way raise a conflict of interest between Consultant and OSI.

6. Indemnification. Each party will defend, indemnify and hold harmless the other party, its
officers, directors, employees and agents from and against any and all losses, liabilities,
damages, expenses and costs (including reasonable attorney’s fees) (“Losses”) directly caused by or
resulting from a material breach of this Agreement by such party, except to the extent such Loss
was caused by the gross negligence or willful misconduct of the party (including its officers,
directors, employees and agents) seeking indemnification. Each party will notify the other party
promptly upon learning of a claim, demand, suit, or proceeding that might give rise to a Loss, and
the potentially indemnifying party may control defense and settlement thereof provided it does so
diligently, in good faith and using reasonably experienced counsel with expertise in the relevant
field. The potentially indemnified party will reasonably cooperate in such defense and/or
settlement at the potentially indemnifying party’s request and expense and may participate at its
own expense using its own counsel.

7. Term and Termination.

     (a) The initial term of this Agreement shall commence on the Effective Date and expire on the
first anniversary of the Effective Date unless earlier terminated under this Section 7. This
Agreement shall automatically renew for consecutive annual periods of one year, unless either party
delivers written notice of termination prior to the applicable expiration date of the this
Agreement.

     (b) Consultant may terminate this Agreement for a material breach by OSI upon thirty (30)
days’ written notice specifying the breach unless such breach is cured within such 30-day period.

     (c) OSI may terminate this Agreement at any time and for any reason or no reason, upon written
notice to Consultant.

     (d) Expiration or termination of this Agreement shall not affect accrued rights or obligations
of the parties. Sections 4, 5, 6, 7 and 8 shall survive termination or expiration of this
Agreement.

8. General.

     (a) This Agreement shall be interpreted and enforced in accordance with the laws of the State
of New York, regardless of any choice of law principles. The parties will submit any dispute or
claim arising under this Agreement to the exclusive jurisdiction of the U.S. federal or New York
state courts within the New York counties of New York or Nassau, and the parties hereby submit to,
and waive any objection to, personal jurisdiction and venue in such courts for such purpose.

     (b) Any purported assignment or delegation by Consultant of this Agreement in whole or in part
without the prior written consent of OSI shall be void. OSI has the unconditional right to assign
this Agreement if there is no resulting material change in the scope of the Services. This
Agreement shall be binding upon the parties, their successors and their permitted assigns.

     (c) All notices under this Agreement shall be in writing and shall be deemed given upon
personal delivery, delivery by internationally- or nationally-recognized bonded courier service, or
seven (7) days after sending by certified or registered mail, postage prepaid and return

3

 

receipt requested, to the following addresses of the respective parties or such other address
as given by notice under this Section 8(c):

	 	 	 
	OSI:

	 	OSI Pharmaceuticals, Inc. 

At the address set forth at the beginning of this Agreement 

Attention: General Counsel
	 
	 	 
	Consultant:

	 	Walter M. Lovenberg, Ph.D.

At the address set forth in the records of the Company

     (d) During the term of this Agreement, Consultant agrees to abide by the terms of OSI’s
Statement of Company Policy on Securities Trades By Company Personnel and Directors.

     (e) During the term of this Agreement, Consultant will not (i) improperly use or disclose any
proprietary information or trade secrets of any former or concurrent employer or other person or
entity and (ii) bring onto the premises of OSI any unpublished document or proprietary information
belonging to any such employer, person or entity unless consented to in writing by such employer,
person or entity.

     (f) Consultant recognizes that OSI has received and in the future will receive from third
parties their confidential or proprietary information subject to a duty on OSI’s part to maintain
the confidentiality of such information and to use it only for certain limited purposes.
Consultant agrees to hold all such confidential or proprietary information in the strictest
confidence and not to disclose it to any person, firm or corporation or to use it except as
necessary in carrying out Consultant’s work for OSI consistent with the OSI’s agreement with such
third party.

     (g) This Agreement sets forth the complete, final and exclusive agreement between the parties
and supersedes and terminates all prior agreements and understandings between the parties. No
amendment to, or waiver of right under, this Agreement is effective unless in writing signed by
authorized representatives of the parties. No waiver by a party of any breach of this Agreement
shall be a waiver of any preceding or succeeding breach. No waiver by a party of any right under
this Agreement shall be construed as a waiver of any other right. If any provision of this
Agreement is judicially or administratively determined to be unenforceable, the provision will be
reformed to most nearly approximate the parties’ original intent, but otherwise this Agreement will
continue in full force and effect.

     (h) Consultant’s relationship with OSI will be that of an independent contractor, and nothing
in this Agreement shall be construed to create a partnership, joint venture, or employer-employee
relationship. Consultant is not the agent of OSI and is not authorized to make any representation,
contract, or commitment on behalf of OSI. Consultant will be solely responsible for all tax returns
and payments required to be filed with or made to any federal, state or local tax authority with
respect to Consultant’s performance of services and receipt of fees under this Agreement. If
Consultant is a natural person, (i) Consultant will not be entitled to any of the benefits that OSI
may make available to OSI employees, such as group insurance, profit-sharing or retirement
benefits, (ii) OSI will regularly report amounts paid to Consultant by filing Form 1099-MISC with
the Internal Revenue Service as required by law, and (iii) OSI will not withhold or make payments
for social security, make unemployment insurance or disability insurance contributions, or obtain
worker’s compensation insurance on Consultant’s behalf; provided however, that nothing in this
Section 8(h) shall affect any benefits that Consultant is entitled to (including without
limitation, any retirement benefits) as a result of his prior service as a director of the Company.
Consultant accepts exclusive liability for complying with all applicable state and federal laws
governing self-employed individuals, including obligations such as payment of taxes, social
security, disability and other contributions based on fees paid to Consultant, its agents or
employees under this Agreement, and will defend, indemnify and hold harmless OSI

4

 

from and against any and all such taxes or contributions, including penalties and interest.

     (i) This Agreement may be executed simultaneously in two or more counterparts, each of which
shall be deemed an original, but all of which together shall constitute one and the same
instrument.

The parties hereto have entered into this Agreement as of the Effective Date.

	 	 	 	 	 	 	 	 	 	 	 
	CONSULTANT	 	 	 	OSI PHARMACEUTICALS, INC.	 	 
	 
	 	 	 	 	 	 	 	 	 	 
	By:

	 	/s/ Walter M. Lovenberg
 

Name: Walter M. Lovenberg, Ph.D.
	 	 	 	By:
	 	 /s/ Colin Goddard
 

Name: Colin Goddard, Ph.D.
	 	 
	 

	 	 	 	 	 	 	 	Title: Chief Executive Officer	 	 

 

5

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00137-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00137-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00137-of-00352.parquet"}]]